The short answer
Retatrutide is not approved by the FDA or any other major regulator. In its second-quarter 2026 results, Eli Lilly said it plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027, describing the clinical data package as complete. No approval date has been announced, and any date you see online is an estimate.
Source: Eli Lilly second-quarter 2026 results (SEC filing, August 2026) ↗
How long FDA review usually takes
Under the FDA’s standard user-fee goals, an application for a new drug of this kind is reviewed within 10 months of a 60-day filing period, about 12 months in all, or about 8 months with priority review. A submission in early 2027 would therefore point to a decision around early 2028 on a standard timeline, or late 2027 with priority review. The FDA can also ask for more information, which can push a decision back.
There was a faster route. In April 2026 the FDA approved Lilly’s GLP-1 pill orforglipron (Foundayo) 50 days after filing under its National Priority Voucher pilot, which targets decisions in about two months. On November 12, 2026, Reuters reported, citing six sources and internal documents, that the FDA has shelved that program and that career FDA scientists again oversee the review timelines of the drugs still in it. HHS told Reuters the pilot is ongoing. Lilly has not said that retatrutide has a voucher, so the standard timeline above is the one to go by.
Source: FDA PDUFA VII review goals ↗
Source: FDA: first approval under the National Priority Voucher program, April 2026 ↗
Source: Reuters: FDA shelves priority voucher program, November 12, 2026 (via Investing.com) ↗
What the application will rest on
Lilly’s phase 3 TRIUMPH trials are the core of the case. In TRIUMPH-1, 2,339 adults with obesity but without diabetes lost an average of 17.6% to 25.0% of their weight over 80 weeks across three dose levels, versus 3.9% on placebo. In TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes lost 11.9% to 18.8%, versus 5.1%. In TRIUMPH-4, in people with obesity and knee arthritis, knee pain fell more than on placebo alongside 20.0% to 23.7% weight loss.
Stomach and gut side effects were the most common problems in every trial. All were funded by Lilly, and none was long enough to show effects on heart attacks, strokes or long-term safety.
Source: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity ↗
Source: Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity ↗
Until then, nothing sold as retatrutide is the real thing
Because it isn’t approved, there is no legal retail retatrutide in the US. The FDA says retatrutide cannot be used in pharmacy compounding and has warned telehealth companies, ingredient distributors and outsourcing facilities over it. The trial results describe Lilly’s manufactured drug, not vials sold online under the same name.
Testing shows why that matters. In October 2026, CBS News had vials sold as retatrutide lab-tested, and one from a corner store contained a chemical filler and bacteria. In November 2026 Australia’s drug regulator found vials labelled as retatrutide held less of the drug than stated, with large differences between samples.
Source: FDA: concerns with unapproved GLP-1 drugs ↗
Source: CBS News, October 2026 ↗
The legitimate way to get it now
Before approval, the only legitimate access is through a registered clinical trial. ClinicalTrials.gov lists retatrutide studies, including where they are recruiting. Anyone interested should talk with a clinician about trials or about approved options such as semaglutide and tirzepatide. PepsRadar gives no dosing, sourcing or treatment advice.
Continue with the original research
Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.

